Q3 2023 Charles River Laboratories International Inc Earnings Call
Ladies and gentlemen, thank you for standing by and welcome to the Charles River Laboratories third quarter 2023 earnings Conference call. This call is being recorded at this time all participants are in a listen only mode. After the speaker's presentation, there will be a question and.
Session to ask a question. During this period, you will need to press star one on your telephone if you want to remove yourself from the queue. Please press star. Two lastly, if you should need operator assistance. Please press star Zero I would now like to turn the conference over to our host Todd Spencer Vice President of Investor Relations.
<unk>. Please go ahead.
Good morning, and welcome to Charles River Laboratories third quarter 2023 earnings Conference call and webcast. This morning, I am joined by Jim Foster Chairman, President and Chief Executive Officer, and Flavia, Pease Executive Vice President and Chief Financial Officer. They.
They will comment on our results for the third quarter of 2023. Following the presentation. They will respond to questions. There is a slide presentation associated with today's web site, which is posted on the Investor Relations section of our website at IR Dot C River dotcom it.
A webcast replay of this call will be available beginning approximately two hours after the call today and can also be accessed on our Investor Relations website. The replay will be available through next quarters conference call.
I'd like to remind you of our safe Harbor, all remarks that we make about future expectations plans and prospects for the company constitute forward looking statements under the private Securities Litigation Reform Act of 1995.
Actual results may materially materially differ from those indicated.
During the conference call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of the core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP.
In accordance with regulation G. You can find the comparable GAAP measures and reconciliations on the Investor Relations section of our website.
I will now turn the call over to Jim Foster.
Good morning.
We reported third quarter organic revenue growth was four 1% and earnings per share of $2.72.
Both of which exceeded our prior outlook.
As anticipated growth rates decline from first half levels, reflecting a difficult comps from last year and the moderating demand that is affecting our businesses. This year.
Looking at the biopharmaceutical end market environment, we believe certain demand trends slowed showed some early positive signs.
Clients also remained cautious with their spending.
Biopharmaceutical clients are continuing to re prioritize their pipelines and in some cases conserved cash.
Streamline their cost structures.
Led to a meaningful impact on some of our businesses this year.
Including discovery services, and our manufacturing segment and.
And began to have a more a discernible impact on the RMS business in the third quarter.
We believe the current client spending patterns will persist in the near term. However, we are also seeing some early encouraging signs starting to emerge which support our belief that the demand environment will stabilize.
And the safety assessment business, we were pleased to see sequential improvement in both the steady cancellation rate and the net book to Bill ratio in the third quarter.
Favorable trends that supported by external indicators, including a stable biotech funding environment.
Third quarter was the second consecutive quarterly increase in biotech funding.
Mailing 12 month basis.
Venture capital investments.
I will now provide highlights of our third quarter performance we.
We reported revenue of one point or $3 billion.
The third quarter of 2020, 338% increase over last year organic revenue growth of four 1% was driven by all three business segments led by a mid single digit increase in the DSA segment.
As I mentioned earlier, the third quarter growth rate was affected by a difficult comparison to last year.
<unk> organic growth of 15, 3% in the third quarter of 2022.
By client segment third quarter revenue growth was driven by solid demand from global Biopharma clients and academic institutions.
Yeah. This has been the case throughout the year the growth rate for small and midsize biotech slowed as these clients are being more selective with their spending.
So biotech clients last year also outpaced all other client segments, driving a particularly difficult comparison in the <unk>.
Second half of the year.
Operating margin was 25% an increase of 10 basis points year over year. This slight improvement was driven primarily by the DSA segment as well as lower unallocated corporate costs.
Improvements were largely offset by margin pressure in both the RMS and manufacturing segments.
Earnings per share were $2.72 in the third quarter, an increase of three 4% from the third quarter of last year.
This exceeded our prior outlook due primarily to the top line performance.
In addition, the year over year headwind from interest expense is beginning to dissipate.
We have tightened our revenue and non-GAAP earnings per share guidance ranges for 2023.
We move into the final quarter of the year, we had narrowing our organic revenue growth guidance to a range of five five to six 5%.
non-GAAP earnings per share guidance to a range of $10 50.
To $10 70.
Which raises the bottom end and trends the top end of our prior range by <unk> <unk> per share respectively.
The guidance update is primarily due to shifts in the gating of our forecast between quarters and the favorable impact of lower third quarter cancellations in our safety assessment business.
Being largely offset by a reduced outlook for our manufacturing solutions segment in the fourth quarter.
I'd like to provide you with additional details on our third quarter segment performance beginning with the DSA segment's results.
DSA revenue in the third quarter was $664 million increase of five 3% on an organic basis safety assessment business continued to drive DSA revenue growth with contributions from base pricing and highest steady volume.
Given by non NHS related work and post IND studies.
And HP pricing with a modest benefit to the growth rate and as I will discuss shortly and HP steady volume declined year over year.
Discovery services remains an integral component of our end to end early stage portfolio.
Because it enables us to forge relationships with clients at earlier stages of the R&D process. However.
The business continues to be impacted by the overall biopharma demand environment.
Clients focus on post A&D work and getting their drugs to the clinic.
To the detriment of discovery spending.
As I mentioned earlier, we saw some early signs of a more favorable demand trends in the third quarter for our safety assessment business.
Installation rate improved sequentially.
And was at the lowest level since the second quarter of 2022.
The net book to Bill ratio also improved sequentially, but remained below one times.
As a result, the DSA backlog declined in the third quarter to $2 6 billion from $2 8 billion at the end of the second quarter. However is a lower cancellation suggest clients appear to be moving further along in their pipeline re prioritization processes.
Which we believe will lead to a higher quality and more reliable book of business.
With a net book to Bill remaining below one times, we believe the current demand trends will persist.
The near term, including in the fourth quarter, which as a reminder, already faces a difficult comparison to DSA organic growth of 26, 5% reported last year.
Overall, we believe stabilizing demand trends and significant backlog coverage will enable us to achieve our financial targets, including high single digit DSA organic revenue growth for 2023 wishes.
Which is above our prior outlook for this segment.
The DSA operating margin was 27, 2% in the third quarter.
100 basis point increase from the third quarter of 2022.
Increase continued to be driven by operating leverage associated with higher revenue in the safety assessment business.
Before moving onto RMS I'd like to comment on our NIH related study work.
At our Investor Day in September we provided some information around the benefit from NHK pricing on our DSA revenue growth rates, we believe that additional information would be useful for investors and analysts to gain a better understanding of the impact of NHI pricing and then HP related safety assessment studies on our business.
Over a three year period, ending in 2023, and HP pricing is expected to benefit DSA revenue growth by a total of just $230 million.
Approximately 30% of our total DSA revenue growth since 2020.
Without the impact of NH P pricing DSA revenue would still have increased at a high single digit growth CAGR since 2020.
In total and HP safety assessment steady revenue, which includes both services and the embedded in HP revenue is expected to represent approximately 30% of DSA segment revenue in both 2022 and 2023.
And HP pricing has rapidly escalated since 2020.
Due to both an HP supply constraints and a continued increase of biologic drugs in development.
Supply constraints began in China around the pandemic intensified last year due to the Cambodian an HP supply situation in the U S.
This has caused an HP pricing to increase.
By approximately $20000 per model.
Aggregate since 2020.
In 2023, we expect to utilize approximately 11400, NH peace and safety assessment studies worldwide.
Represents a reduction of approximately 25% from over 15000 in the prior year, principally driven by the current level of biopharmaceutical demand and our clients focus on their post A&D safety assessment work.
<unk> generates higher service revenue per model due to the longer term nature of these studies with fewer NH piece are used to generate that service revenue.
Our longstanding strategic imperative of the company is responsible animal use which includes modifying or reducing animal usage with.
Responsible animal use is firmly embedded in our commitment to animal welfare and the four Rs principles.
And its adoption accelerated this year as a result of the NHS supply constraints. One example of our progress is the introduction of virtual control groups for toxicology studies virtual control groups or VC Gs replace the animals and control groups with existing randomized datasets and statistic.
<unk> evaluations it will take some time to adapt but we are having active discussions with our clients about D. C. G.
As many of you are aware, we are committed to providing additional disclosure on HP sourcing and a comprehensive update on our strategic initiatives in early 2024.
The timing of the strategic update will be ideal as we recognize the industry is changing and the shifts are causing disruptive technologies to emerge and societal needs to evolve.
With the industry at an inflection point, we will reinforce our critical role in preclinical drug development and maintain our leadership position, we will do this by leading with science.
<unk> committed to our essential mission of creating healthier lives and ensuring patient safety.
And by consistently challenging ourselves to raise the bar.
And as we look to the future we will be focused on ensuring a sustainable supply chain.
Particularly for in Hps, we will also pursue a longer term strategy to lead the industry in adopting animal alternatives.
Our team is diligently working to continue to enhance our processes and key initiatives. In these areas. We have already made several investments in non animal technologies ranging from <unk> trillion launched this summer branded taxing the test detection testing to our technology partnerships with Zillow for discovery AI.
Past that quest for next Gen sequencing for in vitro viral study safety testing.
And <unk> for three D tumor model and we look forward to sharing and HP strategic update in early 2024.
Alright, Thats revenue was $186 $8 million, an increase of three 2% on it.
Organic basis over the third quarter of 2022. This is below the year to date high single digit revenue growth rate for two primary reasons.
Slowing demand for mid tier clients, including biotechs, and <unk> and the timing of an HP shipments within China as we anticipated last quarter.
The timing of NIH P shipments within China as transitory, we expect <unk> revenue in China will improve in the fourth quarter, although some shipments will slip out of 2023 for the year, we expect RMS organic revenue growth will be in the mid to high single digit range.
In the third quarter, we generated revenue growth and a small research model.
<unk> business and in the services business.
My client segment demand from global Biopharma clients and academic institutions remained robust.
Rove RMS revenue growth, but as I mentioned this was offset by a mid tier clients affected by the broader biopharma demand environment as well as by softer demand from government accounts.
Small molecules revenue increased across all geographic regions, including China, principally driven by price.
Services business continued to report healthy growth led by Insourcing solutions in a credible operations.
<unk> sites or a flexible by various rental space remain well utilized overall and continue to generate significant year over year revenue growth.
In the third quarter, the RMS operating margin decreased by 460 basis points to 18, 9%.
The significant decline was driven by the mix of business was favorite academic clients.
Sourcing solutions business as well as the timing of NH P shipments within China.
We expect the RMS operating margin will rebound in the fourth quarter due in part to the timing of the China and HP shipments. In addition, as we mentioned at Investor Day, We are reviewing the profitability of certain insourcing solutions contracts, which should benefit the RMS operating margin in the future.
Revenue for the manufacturing solutions segment was $175 $7 million, an increase of 9% on an organic basis compared to the third quarter of last year.
This segment is experiencing softness across the broader end markets, which we attribute to a post COVID-19 slowdown from Biopharma manufacturers see demos and the suppliers.
Market conditions started to more noticeably impacted microbial solutions business in the third quarter clients, particularly see demos are cutting costs.
Part of that covered destocking metrics, and reducing testing volumes and fewer programs advance into the clinic.
These clients must continue to manufacture commercial products. So we believe the long term growth trends for our manufacturing segment will reemerge after a period of right size.
For microbial solutions to global Biopharma demand environment is affecting.
Brian just save endotoxin.
Testing product line.
And as clients reduced reduced both testing volumes and investments in new instruments. This includes China, where we have a small microbial operation. Unlike many life science instrumentation companies have seen a decline in client demand. However, other areas of the business such as <unk> microbial identification services.
<unk> continued to perform well.
Third quarter trends in biologics testing with similar to those experienced since the beginning of the.
The sector continued to be challenged by the tighter funding environment, which is resulting in clients re prioritizing projects and reducing demand for services that can be conducted at various times during the development process, including viral clearance and cell death.
While not immune to the end market challenges and the other manufacturing businesses.
The cell and gene therapy, CMO business had another solid quarter at strong double digit growth rate in the third quarter reflected the success of the initiatives. The CMO team has implemented since the beginning of 2022 to improve performance.
We're working diligently to continue to expand our <unk> sales pipeline of new products and are pleased to have cleared several regulatory audits in recent months, including European EMA approval Memphis site for the production of the second cell therapy product.
We believe that successful regulatory audits will generate additional client interest and support our expectation that we will add new commercial clients.
The manufacturing segment's operating margin declined by 410 basis points year over year to 24, 5%.
The third quarter of 2023, but did improve again sequentially the year over year margin decline reflected the lower revenue growth rate and a softer demand trends across the manufacturing end markets.
We are intently focused on driving operating margin improvement in the manufacturing segment.
The profitability of the CMO business.
As this segment is expected to be the largest contributor to achieving our 2026 margin targets.
We believe our leading position as an outsourcing partner for our clients' drug discovery and non clinical drug development efforts is helping us to manage in the current demand environment, the IND, enabling and associated non clinical services that we provide are mandatory to help clients advance their programs into the clinic and eventually.
<unk> two commercialized drugs.
Our portfolio also differentiates us in the marketplace.
Cause of our unique focus on early stage R&D solutions, and our ability to distinguish ourselves scientifically.
We believe that these attributes combined with our continued ability to leverage the significant DSA backlog will enable us to achieve our financial targets.
<unk> proposition of delivering exquisite science, and driving greater efficiency and speed to market continues to differentiate Charles River in the marketplace and is reinforced with today's more budget focused client base to.
To conclude I would like to thank our employees for their exceptional work and commitment.
Our clients and shareholders for their continued support.
Now Flavia will provide additional details on our third quarter financial performance and updated 2023 guidance.
Thank you Jim and good morning, before I begin may I remind you that I'll be speaking primarily to non-GAAP results, which exclude amortization and other acquisition related adjustments costs related primarily to restructuring actions.
Gains or losses from certain venture capital and other strategic investments and certain other items.
Many of my comments will also refer to organic revenue growth, which excludes the impact of acquisitions divestitures and foreign currency translation.
We're pleased with our third quarter results, which included $4, 1% organic revenue growth and an operating margin of 25% representing a 10 basis point increase on both a year over year and sequential basis.
non-GAAP earnings per share of $2.72 for the quarter represented a three 4% increase over the prior year.
As expected increased interest expense, a higher tax rate and the divestiture of the avian vaccine business.
To restrict year over year earnings growth rate.
The headwind is beginning to dissipate as we anniversary last year's interest rate increases.
Our third quarter results outperformed our prior outlook, but as Jim discussed we remain cautious with regard to the biopharmaceutical end market demand environment.
Our updated outlook for the year reflects our normal practice of narrowing our guidance ranges as we move into the fourth quarter as well as a shift in the gating of our forecast between the third and fourth quarters.
This is due in part to lower cancellations and study slippage than forecasted in the third quarter in the DSA segment offset by a reduced outlook for the manufacturing segment in the fourth quarter.
The cumulative effect of these factors, we have narrowed our revenue growth and non-GAAP earnings per share guidance for the full year.
We now expect revenue growth in a range of two five to three 5% on a reported basis and five five to six 5% on an organic basis, which represents the low end to midpoint of our prior ranges.
We expect continued pressure in the manufacturing segment, reflecting the softer demand trends.
<unk> in the microbial solutions business, which we believe will be partially offset.
By a more favorable outlook.
DSA segment for the year.
We expect that the consolidated operating margin will be modestly lower than in 2022.
Melting and non-GAAP earnings per share guidance in a range of $10 50 to.
So $10.70 compared to our prior outlook of $10 32.
$10.90.
We'll continue to manage the business in a disciplined manner with a focus in setting achievable financial targets protecting our operating margins by managing cost and driving greater efficiency remaining disciplined with our investments taking share and implementing other initiatives to improve performance.
And manage effectively in this environment.
Continue to evaluate our operations and we will appropriately manage our cost structure to align with the current demand environment.
Restructuring actions implemented this year I expect it to generate approximately $40 million in annualized cost savings.
Our updated revenue growth outlook reflects slight revisions for each of our segments as I just referenced we are reducing the outlook for our manufacturing segment to be flat to low single digit organic growth from our prior outlook in the high single digits.
But the RMS segment, we have widened the bottom end of our outlook to mid to high single digit organic growth.
This reflects the timing of NH b shipments in China, some of which may be deferred to 2024.
Our EMS segment also experienced a more discernible impact from mid tier biopharma clients as softer demand.
Our improved outlook for the DSA segment to high single digit organic revenue growth principally reflects the lower cancellations and study slippage in the third quarter that I referenced.
I will now provide some additional details on the non operating items that affected our third quarter performance.
Unallocated corporate costs in the third quarter totaled $48 million or four 7% of total revenue compared to five 8% of revenue last year.
The decrease was primarily due to benefits achieved to all virtual power purchase agreements or ppas.
Despite the favorability in the third quarter, we continued to expect unallocated corporate costs to be approximately 5% of total revenue for the full year.
As we announced in October we have achieved 90% renewable electricity globally through our solar the PPA in North America, and our wins the PPA in Europe. These.
These agreements have enabled our facilities in those regions to achieve 100% renewable electricity, providing a key component of our efforts to reduce scope, one and two greenhouse gas emissions.
The third quarter non-GAAP tax rate was 21, 6% representing 840 basis point increase from the same period last year.
The higher tax rate year over year was due primarily to the geographic mix of earnings.
However, the tax rate was favorable to our expectations, principally because of discrete tax benefits related to U S. R&D tax credits.
For the full year, we now expect the tax rate will be at the low end of our prior range or approximately 22, 5% due primarily to the discrete tax benefits.
Total adjusted net interest expense for the third quarter was $32 $4 million.
Representing a decrease of $1 $2 million sequentially due primarily to debt repayment.
The full year, we have narrowed our total adjusted net interest expense outlook by $1 million to a range of $131 million to $133 million.
Any further rate increases by the federal reserve before the end of the year will not have a meaningful impact on our 2023 results.
At the end of the third quarter, approximately 80% of our $2 5 billion in.
Outstanding debt was at fixed interest rate.
Our gross and net leverage ratios.
Both approximately one nine times at the end of the third quarter.
Free cash flow was $139 $5 million in the third quarter compared to $64 million last year.
Year over year increase was primarily due to favorable changes in working capital as well as lower capital expenditures.
For the year, we have narrowed our free cash flow guidance to a range of $340 million to $360 million.
Capital expenditures were $65 $9 million in the third quarter.
Impaired to $72 $4 million last year.
For the year, we now expect capex to be in a range of $330 million to $340 million or below our prior outlook of $340 million to $360 million, we continue to take.
Disciplined approach to managing our capital deployment and are committed to aligning our capacity and capital investments with the current demand trends.
A summary of our updated financial guidance for the full year can be found on slide 37.
With one quarter remaining the year, our fourth quarter outlook is effectively embedded in our guidance for the full year.
For the fourth quarter, we expect revenues to decline by nearly 10% on a reported basis.
A mid single digit rate on an organic basis.
This will result in flattish year over year organic revenue growth in the second half of the <unk>, which is consistent with the outlook provided in August.
non-GAAP earnings per share I expect it to be in a range of $2 <unk> to $2 50.
Fourth quarter outlook, largely reflects a very challenging comparison to the prior year. When we reported organic revenue growth of 18, 8%, including DSA growth of 26, 5%.
In conclusion, we're pleased with our solid third quarter performance, which is evidence of the resilience of our business. Despite a cautious biopharma spending environment as growth rates normalize to pre pandemic levels. We will continue to manage our business prudently in response to the challenges we have seen in the <unk>.
Broader market environment.
Diligently to achieve our financial targets. Thank you.
That concludes our comments, we will now take your questions.
At this time, if you would like to ask a question. Please press the star and one you touched on the phone you may remove yourself from the queue at any time by pressing star to once again that is star and wanted to ask a question. We will take our first question for Eric Coldwell with Baird. Your line is now open.
Thank you very much good morning, and.
Truly appreciate all the additional details on the in Hp's I'm curious in <unk> could you provide commentary on the gross awards in DSA, where those.
Positive above one below one just any color on gross bookings in the quarter.
And then on the backlog $2 6 billion I'm wondering if you have additional thoughts on where and when that backlog may stabilize at what level, what how long it might take for the <unk>.
Net reductions to to come to an end. Thank you.
Good morning, Eric.
Yes, the gross bookings were above one in the third quarter.
And we also as you saw in our prepared remarks had a sequential improvement in net book to bill in the quarter. So the backlog came down a little bit from the second quarter. It's at $2 6 billion now it was $2 eight in the second quarter. So I think it is.
Rates that things are stabilizing and we're reverting back to their pre COVID-19 enormous we have been talking about.
Jim if I could just jump in with one more.
You had an investor day, not too long ago, some new updates here on the.
Timing of <unk> impacts may be some additional market change over the last month or two.
Just curious does.
Anything youre seeing today change your outlook on DLR Pea that was provided.
Just a while ago achieved ability confidence levels and then specifically on 2024 I know you plan to give guidance.
Later, but street's hovering around $11 of earnings I think this update might provide some controversy about whether that's a realistic target and I'm just comfort with high level views on.
Your comfort levels with where Street Street expectations are for next year. Thank you.
So Eric we feel.
Feel confident about our three year guidance.
You just gave.
Those numbers.
Tivo bolt.
Both on a segment basis on a total company basis.
And I would say that.
Relative view 24, which we talked about a little bit.
On that on the call.
Significantly change but.
It's a complex market environment.
Fourth quarter earnings.
At a month.
So it's really too early to provide any more details on 24, but we feel good about the three year numbers.
Okay. Thank you very much.
Thank you we'll take our next question from Elizabeth Anderson with Evercore. Your line is now open.
Hi, guys. Thanks. So much further question just in terms of DSA bookings I had just to follow up on Eric's question do.
<unk> and <unk>.
<unk> from like push out your timing issues I just wanted to make sure that we're just looking at everything onto that as like an apples for apples basis and secondarily can you talk about the cash flow in the quarter.
A little weaker than we had been expecting so I just wanted to make sure I understand all stood out all of the puts and takes there. Thank you very much.
So we.
Yes, slippage and cancellations is not always that way.
Talked about that a lot.
Yes.
Definitely been higher this year, but we're seeing a slowdown in cancellations.
We definitely saw that third quarter. So pleased to see that so it feels like things are normalizing, we're kind of getting back to pre COVID-19.
Cadence.
We certainly want to finish the quarter.
And.
Put it an apostrophe after that period after that.
No.
Yeah.
It's always part of the business got more pronounced because we had steady volumes were booking out 18 to 24 months.
In some ways that was really nice in some ways, though is probably too long because yes, we saw client just booking slots would not necessarily no.
Let's just say out of the study and often when I got to the good.
A point of actually commit it didn't have a study so that's been a little bit disruptive so.
We've got pretty good backlogs now.
As long as they were but not assure that February years ago.
Possible to tell where that's going to settle out, but it's moving towards a.
A better place with more predictability more consistency and probably.
A more normal cancellation rate.
Thank Claudia will answer the other part of that question good morning Elizabeth.
On free cash flow in the quarter actually was pretty solid.
Solid we reported about 100 close to $140 million and that was up almost 80 million or 130% versus prior year Aldo.
Last year was a relative slow base.
For the year cash flow.
<unk> is a little pressured.
Some movement on working capital we.
Receivables and inventory and timing of that.
But I think it's still a very solid.
Performance, we actually have lowered our capex for the little bit guidance as you saw.
To reflect.
Modulation of our investment in capacity given the current demand environment in Q3, Capex was a little bit.
Above 6% of sales, which is below what we've been.
<unk> told you all at Investor day that our target would be 7% to 8%.
We are navigating the current demand environment well.
Fortifying.
Our.
Performance.
And we will deliver solid free cash flow for the year.
Youre not seeing an incremental slowdown in like farm that payments or biotech payments given the current environment and then that is that capex. The way to think about things going forward just to double click on two things you said that.
Yes, so I'll parse those two comments out so we are not seeing any impact or any significant impact with regards to bad debt or any similar metrics of credit worthiness.
There is nothing unusual.
Insignificant in the receivables side.
Then from a capital perspective.
We're not.
Coming off of the 7% to 8% that we provided about a month and a half ago Im just saying that relative to that we were lower in the third quarter.
Got it thank you so much.
Thank you we'll take our next question from Derik de Bruin with Bank of America. Your line is open.
Hi, Good morning, and thank you for taking my question.
Hey, Jim I appreciate the additional <unk>.
<unk> come in or on the NH piece, but I think the key question investors have is what's been a benefit for margins and EPS in 2019 and what happens.
When pricing goes back I mean rough back of the envelope.
You can.
Checking my math it looks like it's about a $3 benefit this year to earnings.
Yes, assuming the margins are similar but I assume they're accretive I really think that would really help clear. The air. If you just sort of like talked about what how you sort of think about pricing trends I know, it's not going to go back immediately to.
Prices are going to fall back, but I do think this is like the one question that keeps coming up and investors is like what does EPS looks like as an HP pricing normalizes.
Alright got it.
Yeah, I'll start and then Jim can comment.
No I think it's a little bit of an impulse and possible when and if prices will come down.
We.
As I think we provided in our additional disclosures price has been a benefit but perhaps not as much of a benefit as people have.
Predicted we have.
Diversify supply.
Base, which helps mitigate and manage help us mitigate and manage through price fluctuations and volatility.
As we said in our Investor day, we have.
Taken into consideration a modulation of pricing of NH b in our outlook. So we already took that into consideration as we provided you on our <unk> numbers for the next three years.
More than that.
I don't know.
I have any additional comments Jim.
I mean, I think because we've.
The prices have.
Risen dramatically.
Some of that.
Reflected.
Most of that is passed through.
We think that the prices will flat moderate perhaps be reduced because there are sufficient.
We still think we'll get price besides.
Incremental price for foreign HP since we have for the last few years.
Volume and mix as a result of the types of studies.
What the duration is so.
There has been a benefit but I think it's.
More modest people.
<unk> are anticipating.
I think that's really all that we should say.
We really like to stay away from pricing.
Great Okay. Thanks.
And just switching to something different as a follow up.
Can you sort of quantify what the.
Anyway, how much microbial was down in.
In the business and how much of that was China versus the rest of the world and also what was the impact to Rms.
And HP push out to China and <unk>. Thanks.
Yes so.
Without giving you the actual numbers.
The China <unk> sales.
Are not consistent so.
Shift from quarter to quarter.
<unk>.
So thanks.
Thanks, a lot.
Annual basis, so we're likely to see more of that happen in the fourth quarter some of that might slip over.
20.
2024 first time in the first part of your question on.
<unk> microbial so yes, sir.
Several things.
For sure some impact from China, and we have a small but not we have a small but.
Profitable and interesting Chinese business, which has had just some difficulty.
Terms of supply with.
The regulations.
We should be we should people be past that.
Like many parts of the business I mean the.
The microbial business is providing a lot of it lease.
Testing for drugs that go into the clinic or have been approved required by law. That's the good news.
The less good news is that there's less drugs going through that testing.
Modality.
So that has.
We also have clients buy an awful lot of product from us at the end of <unk>.
Last year of course, we don't know at the end of this year will be like but it seems to be sort of an unloading.
Inventory or in fact I think.
Stocks got so much I think that's it.
Probably less.
The business is at an interesting inflection point with the recombinant products being available I think it will take a while for those to get traction but.
Some some aspects of our client base has been looking forward to that we have a very good products. So we feel we feel good about about that so slightly slower growth rate that we would have liked but I think thats kind of consistent with demand that we're seeing across the board, particularly for biotechs.
Darren just.
Just to add.
Specifically on the NH b it.
It is just a modest headwind to the RMS revenue in the third quarter.
We're not going to specify the amounts, but it's it's a modest impact.
And to Jim's point.
While the microbial China business is still relatively small it had been growing nicely for us so that slowdown does affect their microbial growth rate.
Thank you.
Thank you we will take our next question from Casey Woodring with JP Morgan Your line is open.
Great. Thank you for taking my questions. So just a quick follow up I wanted to touch on the bookings.
Gross bookings growth sequentially or did cancellations just drop quarter over quarter, and then I just have one quickly on the revenue per head and HP looks like if we use the numbers that you gave here at 30% of DSA revenue.
Per year is exposed to <unk> and Hps, if you back out the implied for looks like revenue per NH P grew close to 42% year on year in 2003.
Just how should we contemplate revenue per <unk> on a forward looking basis. Thank you.
Yeah.
So I'll maybe take the question on cancellations.
Gross and net book to Bill.
So I think we also stated.
In our remarks.
Cancellation level it does.
Third quarter is the lowest that we've had seen since the second quarter of 2022.
So I think we have been talking about.
A normalization.
Nation of the demand environment people going through their.
Pipeline re prioritization.
Had speculated that that would eventually modulate as Jim said slippage and cancellation is a normal part of the business, but we had certainly seen a.
Higher level of cancellations.
As the backlog extended significantly at its peak 2017 months and so there was a lot of.
I would say rationalization and people.
<unk> their compounds.
The gross book to Bill in the quarter was above one as we said.
And so the lower cancellations did help improve the net book to Bill sequentially in the third quarter versus the second quarter. So I hope that answers. Your question and can you repeat the part about the MSP pricing.
Yes, it was just.
The less in Hps use this year has led to a lot higher.
The amount of revenue per NH piece, so just thinking about that on a forward looking basis.
Just trends there.
Any color around that trend.
Yeah.
Thanks for clarifying that.
The last N HP usage and still on a relative basis higher revenue is driven by the types of studies that we're conducting.
But more so as clients seem to be prioritizing post IMD work.
We are seeing the impact of that into our study it makes us well.
We do a significant amount of post award these studies are longer in nature.
So from a from a mixed perspective, they result in less units, but relatively higher revenue.
<unk>.
Last logos I said, so it really will depend on what happens with the demand.
We.
If clients start going back to <unk> can you see.
Part of higher numbers.
Units being used so its hard for us to predict at this point.
Given that we don't know.
Our clients says I'm going to beat clients are going to be prioritizing their pipeline focusing on <unk> studies.
Thank you we'll take our next question from Patrick Donnelly with Citi. Your line is open.
Hey, guys. Thanks for taking the questions.
So let me maybe one for you just on the margin side gross margins came in a little light I mean was that just to do with the lower manufacturing side and then you guys, obviously offset that with SG&A being quite a bit lower can you just talk about I guess, the moving pieces on those two and right way to think about that going forward.
Sure.
Yes, the gross margin was down in this.
You saw an appropriately pointed.
Manufacturing and also as we commented IMS was a little bit impacted by.
The demand environment.
The growth slowing down to about 8% versus last quarter, putting aside the timing of shipment of NH beads.
So those two businesses were pressured in margin and our ability to leverage fixed overhead. We did have the benefit in G&A and I talked in my prepared remarks about the impact of RV PPA. So we put it altogether DSA had another strong margin quarter for us.
Operating margin expanding 100 basis points year over year. So.
In total we were about pinpoint excuse me 10 bps better at 25 versus Q2 as well as prior year.
There is a little bit of mix of business is that.
As I also indicated in my prepared remarks, we are.
As as all would expect remaining disciplined in ensuring that we adjust our footprint and our infrastructure to the current demand environment, we have implemented.
Some restructurings that will when we're now completed will translate into annualized savings of about $40 million and so if you think about the margin.
As we are right sizing our businesses to the current demand environment is a little bit of a lag in terms of when you're going to see.
The benefit of these actions.
But I think.
We commented that we expect continue to expect Oi to be flat to slightly down versus last year.
And we provided some insight.
<unk> in our Investor day in terms of what we expect for the next three years in terms of margin expansion.
Okay. No. That's helpful. And then maybe just one more quick one on the on the gross booking side can you just help us think about what the gross book to Bill was last quarter again, I'm, just trying to kind of feel out the numbers here without the cancellations on a gross book.
Syed I appreciate it.
Yes, so we havent disclose a specific number to what we have said is growth.
Book to Bill has been above one.
In Q3 as well as Q2, so it continues to be above and as I said to an earlier question.
What influenced the net book to bill to be sequentially up in the third quarter versus the second quarter was the fact that cancellations were lower in the third quarter.
Alright, Thank you guys.
Thank you we'll take our next question from Dave Windley with Jefferies. Your line is open.
Hi, Good morning, Thanks for taking my question and thanks for the additional disclosures I appreciate that very much I wanted to try to.
Follow up on a couple of prior questions. So.
On the.
What kind of cases question I guess on the on the revenue per NH P implied.
Fluffy I understand your point about I think you were talking about like.
Maybe long term car studies or something of that sort that are run longer without needing more animals.
Is that is that the exclusive impact or is.
Is there also like a reuse thats not in the account and I'm thinking if you have 11000 unique animals. For example, and then there are also some reuse of those animals that would also have the effect of lowering that that revenue per annum I just want to make sure I understand the various contributors to these numbers that you've disclosed this morning.
Sure David Good morning, Yes, the primary impact is <unk> card studies repo studies dose.
To last longer so.
We can still get the same revenue with less units. So that's the primary driver.
And those types of studies are both IMT they were up significantly.
In Q3, and they have been up.
Sort of Q3 year to date.
Versus last year as well so that again goes back to my earlier point of clients prioritizing post <unk> work. So we have a reduction in numbers so NH psus.
With a meaningful amount of revenue associated with those just because the studies are much higher value co much longer.
And really essential to be getting trucks through the clinic, so you're a little bit of a shift.
At least for this year.
To say Hello.
We usually have a pretty good balance between.
Post Sandy work.
But that's a really good explanation for why the units for that.
Got it okay.
Jim on the there are couple of comments I think in the deck. This morning about.
Kind of technology references.
I know in the past the general view has been that.
As much as we'd like to be able to.
Spare animals our shifts.
Shift to virtual technologies in Silicon technologies that those are probably a long way off one of your lines in the deck. This morning kind of references that like maybe there's a little bit more promise, there and I wanted to and kind of the we're going to lead the industry context, I wondered if you'd comment on that is M. I <unk>.
We're reading that.
No.
I'm glad you asked us today.
So Charles River has a responsibility to utilize.
Alternative adjunct technologies to the extent that they actually exist in work.
Latest and clients will embrace that and they'll give us decent information.
And so as the largest provider of research models is the largest tax company we have to leave.
So we have multiple investments relatively small except for one multiple investments and a whole bunch of different technologies, particularly AI next generation sequencing three D modeling would be once it come to monarch.
Immediately I met with.
The company yesterday, that's in the AI field, so that's probably going to be another one.
And it's impossible to tell how much traction, we'll get but I do think that.
There's a fair amount to work being done right now and I can see it sooner than later and discovery and we can see it sooner than later and helping our clients identify a lead compound.
And.
Moving away from other drugs that we're working on but probably don't show efficacy in beef.
Are you able to do that with non animal technologies or less animals.
And hopefully that would speed up the whole process of moving towards the clinic. So we feel really good about that David I could guess how far away. This is but I think we'll see some of the discovery impact.
We think that's beneficial for the industry and for us sometime maybe in the next five.
Five years I don't think there will be substantial.
I do think it will be real to the extent to which those technologies work those are likely to be companies that we buy or technologies that we license.
And never is a long time, so I won't use the word <unk>.
From everybody that we speak to we think is highly unlikely.
You're going to see any wholesale.
Replacement of animals, and classic toxicology, just because thats all about safety and a whole animal model appears to be the best use the best way to do that but.
And so the extent to which the nonvolatile technologies ever get any traction Tox I think thats, we think thats way off.
Having said that we're just going to do a lot of work David all of this stuff.
Study right about it utilize it talk to our clients about attached with regulators, but I make multiple shots on goal with these potentially valuable technologies to see what really has has traction. So we're going to continue to talk about it because we do think it's important we do think it's half.
Some demand and we do think that if anybody is going to lead it really needs to be us.
Got it Relatedly one of the other areas that you would hope to I think the lead on was around this parentage testing and provenance of animals is that still relevant or is that is.
Is that kind of faded and not not strategically relevant anymore.
I think that Directionally, that's going to be important.
Not just for.
Regulators, regardless of the country, but for ourselves just to know that and for our clients just to make sure that these animals the purpose spread.
So yes it is.
Going to be sort of slow going to get kind of a.
Our sense from.
Government agencies that they like what we're doing we actually found several places that we could do this.
On a cost effective basis, and really sort of nail down the fact that those animals are as well.
We desire, we got out really fast working on it.
I think the government's going to be a little more slow.
Ill take of even having a conversation with us, but I do think thats something that again, Dave that I think it is essential I think what you have to.
<unk> has a leadership position there.
I think that that.
It's not very complicated by the way as you know this whole.
The whole being able to identify the genetics Gino.
The specific animals is relatively straightforward science, it's a lot of animals. So it is not trivial from a cost point of view, but I think we can do it cost effectively and whatever it is either because of it.
Pass it on.
So.
Still I would say on the background of day, but we'll get back to it at some point for sure.
Got it thank you.
Sure.
Thank you we'll take our next question from Justin Bowers with Deutsche Bank. Your line is open.
Hi, good morning, everyone. So.
With booking a two parter for me.
With the bookings stabilized and.
And sort of if I look at the revenue in safety assessment for the first three quarters does that seem like sort of a good.
Run rate.
Like on the go forward and I, just if I look at what the guidance implies for <unk> for example, and we adjust for.
The extra week last year, it sort of gets.
DSA revenues flat plus or minus.
Q over Q so.
So that's the first one and then just with the improvement.
And the bookings that you're seeing and I understand slower cancellations.
Is there any way to parse that out.
In terms of the nature of those cancellations and how it's sort of improved is it like is it more less of the empty rooms versus.
Programs that are in flight being canceled just any additional color there would be helpful.
The reduction in cancellations is a good thing I hope I hope people are getting that.
Because of capacity limitations demand availability of everything, including NIH peas, and funding seemingly being better whatever last year.
Laura I think we have clients that were really worried that they wouldn't get a slot and so they booked way out.
Which is some of that was good news is some of that was just booking a slot without study so thats disruptive, particularly when you get to the point of.
Planning to set aside a certain number of animals in a cadre of staff and then people cancel and yes. They have a penalty when they canceled that was really great. So I think the normalization of cancellation, which by the way and always always cancellation slippage is obviously out is really a good thing.
Getting back to probably.
Pre COVID-19.
<unk>.
Levels.
As we said a couple of times, it's always been there.
In the calculus.
Our forecasting in our guidance and how we plan for head count.
And allocation.
I think that's I think that's actually a good thing.
Yes.
I would stop short of sort of trying.
Trying to quantify what the growth rate.
Safety assessment business as a forward going basis.
It's a yes.
Yes, it's a business where.
We continue to be the market leader, we continue to get some price we continue to get significant amount of volume I think we just said that.
We have a lot of stuff moving into this post <unk>.
Phase, which is which is fine, but we want both obviously, we don't see <unk> work.
As well, but it's important that we have both long term studies and short term studies I think what's happening is we're going to have a slow normalization of demand.
We have a second quarter with biotech funding is pretty good VC funding its fabulous lot of money coming in from pharmaceutical companies.
So companies as you've heard us say before that have good drugs for unmet medical needs will get funded.
And they don't all have to come to us, but lots of them will come to us. So we feel optimistic about the demand going forward as I said earlier, we stand behind those three three year.
This numbers that we gave.
Our Investor day.
That's sort of speed and cadence of all of this is not particularly clear it hopefully will be a little more clearer as we finish this quarter and talked to you folks in February about specific guidance for next year.
And we can maybe follow up with you later on the DSA revenue for the fourth quarter is just.
To make sure that we get.
Our math correct.
When we provided guidance by segment, it's on an organic basis.
So the TSA at high single digits for the year with the fourth quarter there.
Imply probably a negative growth in the fourth quarter.
And again to remind everybody we had an extraordinary fourth quarter in 2022 with 26, 5% growth with DSA, So theres a bit of comps there.
That impacts it so I don't know if its the impact of the 50 <unk> week when you did your math.
Yes, I was looking I was referring more sequentially versus year over year, but happy to to work through that offline I. Appreciate the question sequentially Youre right it should be flattish.
Okay.
Thank you operator.
Yeah.
Uh huh.
Thank you we'll take our next question from Dan Leonard with UBS. Your line is now open.
Thanks for taking the question.
I want to make sure I fully understand the direction of travel here in DSA and I. Appreciate all the color on gross bookings, but specifically I'd like your thoughts on at what point does the continued weakness in discovery impact your outlook for safety.
Hardly at all.
So I understand why you asked the question so.
Our strategy in coal is very much that discovery is a feeder for safety. So thats, obviously, the essence of your question and a fair one.
Trivial part of the DSA revenue right now, although we love the business.
Good science and good parts and pieces.
In an air pocket right now, but that's going to be transitory.
And just sort of refresh my answer to your question.
If discoveries rocking that's beneficial to our safety business, particularly if we if we hold onto the work and just general generally speaking.
I would say that it's kind of a tale of two cities safety business is actually in this kind of funky economic environment is performing extremely well, we're getting price and share at.
Lots of Big studies.
Capacity is well utilized when I say capacity, but people and space.
So as you think about the future, which I assume you are and if you assume that discoveries the air pocket.
Continuous and I I don't know, whether thats true or not.
Got it.
Don't really fundamentally affect the size and scope growth rate profile.
The safety assessment business and if it comes back strong which by the way Ken.
Ari short notice or no notice it just would be beneficial in some incremental revenue to the sector.
<unk> has I guess the last thing.
Good margins, so I don't want to forget that even though it's slower than we would certainly like it to discovery business is profitable.
Profitable.
Had wonderful growth rate last year, the year before and the year before that.
We are holding our own very well, but it just it's very simple you've got clients big and small emphasizing post IND preclinical work and clinical work.
Just because they have to get some drugs to market to generate more revenue.
And thats sort of an always always but if they don't spend money on discovery, which of course is what they do with biotech only does.
I will spend money on discovery, then they'll have nothing.
Over two years three years, one year from now in the clinic. So it is not our opinion, it's a certainty that the pendulum has to swing back.
A little bit difficult to call because it's definitely related to the.
The funding and the overall comp.
And I think it's related to that much less of it being related to the strength of a scientific modalities, which are really quite powerful.
Really great drugs that these companies were.
Working on that are life saving so.
<unk>.
We'll watch and we'll let you know as soon as discovery begins to come back and as I said, a moment ago It will come back.
Surprisingly fast Saudis assure you don't get a lot of notice on them.
The.
The turnaround time is a pretty good start with pricing.
Yeah.
I appreciate that clarification, Jim and if it's possible to ask an unrelated follow up I was hoping you could frame proportionally how much of your manufacturing business is driven by commercial products versus early stage products that might be more subject to the re prioritization that you talked about on the call.
Yes. Good question. So the <unk> business is all pretty much all clinics.
Not.
And in fact, <unk> got stuff, so it's a little bit different.
And the rest.
Yes, I mean, a big piece of microbial is to la released for commercial products.
So yes for sure.
Less stuff goes through the pipeline is less stuff, it's approved as theyre trying to spend money in the clinic and maybe Manny.
Manufactured or less of their other products it slow success a little bit.
Similarly, with biologics. That's also we have to test us drugs before they go into the clinic.
So just so I don't confuse you, yes, a lot of stuff is focused on the clinic and going into the clinic.
But less than they would.
Otherwise like to go into the clinic, just because the cure, but we've talked about the re prioritization of their pipelines. So even the even the big companies Big pharma, who is well financed.
Has budgets and they are very tight on their budgets.
So we definitely.
Are you seeing just the conservatism on the part of almost our entire client base, who has they haven't really good portfolios they're just.
Just not developing in prosecuting their entire portfolios maybe the way they did in 'twenty one 'twenty two again thats all transitory so as stuff gets through the clinic and into the market.
And when the economy feels better for these folks.
Economists, though.
My own opinion.
Todd useful on this call I do think we'll start to see a lot more spending in discovery.
To answer your question, specifically, you'll see a lot more testing of commercial products and products to go into the clinic.
Thanks, Tim.
Okay.
Thank you we will take our next question from Tejas Savant with Morgan Stanley. Your line is open.
Hey, guys good morning.
Appreciate the time here.
Maybe one on RMS more of a cleanup really.
Flavio can you parse out that 460 bps decline in RMS margin across <unk> timing in China in the academic and sourcing mix I know you mentioned it was mainly the latter as far as top line growth. So is it fair to assume that that sort of flows through to the margin sort of dynamic as well and over what timeframe do you expect to see.
Little bit of help from exiting the lower margin in sourcing contracts I mean is that a 2020 for dynamic or is that more 25 and beyond.
Hey, how are you.
So the Rms.
Impostor, both on top line as well as margin was a combination as I said of.
On the.
Lack of significant shipments of <unk> in China.
As well as a mix of.
Business is.
RMS segment as you pointed out we had a higher growth of some of the lower.
Well on a relative basis.
Lower margin sub segments within Rms.
So we expect that to continue into the fourth quarter, we are seeing from a demand perspective.
More resilience on the larger pharmaceutical.
Clients and government contracts, so that plays into the margin.
And then in the fourth quarter. So we will have an HP shipments on the margin for RMS will pick up in the fourth quarter I think we had telegraphed data or signaled that in Q3.
Going to have any meaningful shipments and therefore, the margin was going to come down.
So again this is <unk>.
Consistent with what we had been expecting.
As far as the government contracts that we expect that we announced in the Investor day.
Our lower margin and that we would.
Be exiting will likely start in the 2020 for Aurizon.
Got it that's super helpful.
And then one on <unk>.
The margin outlook here on a go forward basis, Jim I mean, obviously you mentioned in your prepared remarks, you know manufacturing supported the biggest driver of margin expansion.
Just in light of the <unk> headwinds you're.
Flattish margins next year or be a fair initial assumption I know, it's a complex environment, but you also called out.
<unk> seen a little bit of macro headwinds you are beyond China in hps. So just any directional color for Scott sort of on 2024 margin trajectory would be super helpful. Thank you.
I know it would be super helpful, but after a tough February.
To get that clarity, but.
I appreciate you asking it.
I would say, though we still feel good about the 150 bps over three year period that we.
Sure with all of you during Investor day, the timing of that as Jim said.
It's not linear in that three year horizon.
And obviously the demand environment will play into that as we go into 2024, but we also as I indicated in my prepared remarks have also.
Appropriately adjusted.
Just wanted to ensure we are appropriately reflective of the current demand environment with some of the actions that we took already this year.
I'll, let you take.
Take those pieces and make your estimates for 2024 until we provide guidance in February.
Alright, Thanks, guys I appreciate the time.
Okay.
Thank you we'll take our next question from Max Smock with William Blair. Your line is open.
Hey, thanks for taking our questions.
To start maybe I'll try to get the next question from a lot earlier here just in a different way so youre disclosures imply about $780 million of NH fee related revenue in 2023.
How do the margins associated with this and HP were compare to your DSA operating margins this year and how have the margins on that and HP were changed over the last few years as a result.
The pricing increases on the <unk> side, and then in terms of assumptions for moving forward be curious to hear your take on what you actually have baked in for margins on HP work as part of your midterm guide here given your comments about pricing normalizing. Some here as we move forward. Thank you.
So maybe I'll start and Jim can add.
And I think we commented on this over the last several quarters.
And HPE work on a relative basis.
It has slightly higher margins that some of the other species works that we do.
They tend to be more complex, sometimes longer and so there is a mix impact.
That has been favorable as biologics has grown and that drives higher demand for HP work within all total study.
Species.
We do so that has been a tailwind.
We don't know.
That will continue or not but that is unrelated to the discussions that we've been having on price and I think maybe Jim if you want to add.
Some comments.
Thanks that was fun.
Okay.
Perfect and then maybe just following up on Dan's question from a couple of minutes ago. Here you mentioned the slowdown in discovery doesn't change your strategy in preclinical, but I just wanted to confirm that I heard you right that we're not close to the point, where the slowdown in discovery that we've seen over the last couple of quarters here. It starts to impact gross bookings and safety assessment and then.
Ultimately gets worked its way through the pipeline towards the clinical stage. When do you think do we get to that point and when should we get to when do we start to get concerned I guess that the slowdown we've seen in discovery, we will start to impact preclinical more heavily and eventually clinical trial demand. Thank you.
Don't be concerned.
Yes.
This is not the first time this has happened.
Yeah.
Times are good we see a balanced spending in discovery or development.
That benefits our whole portfolio.
When.
The client base is concerned about.
Revenues they tend to do what's the clinic.
And with regard to pre clinical staff.
<unk> been there before.
And in terms of the growth and development of solidity strength of the companies. They have to go back and spend that discovery. So.
It's just a matter of time.
Possible call. It although we'll obviously have to qualify our operating plan for next year.
Sure.
Our discovery business.
Which we're pleased we're pleased with the scale pleased with what we put together is still trivial by comparison, so it's really going to have no impact on.
The growth of our safety assessment business.
Any tax so as I said before positive about as we continue to.
Alright, Thanks, you have flow through for successful molecule discovery safety.
It could be a benefit.
But I really don't see this being debt.
I suppose if the business was much larger.
90% of our clients were moving stuff from discovery to safety I might give you a different answer.
And we will be there someday, it's not where we are right now so I understand that they are connected.
But its actually useful to look at it.
On a connected basis. So what you see when we report the ESA is essentially primarily.
It gives us results.
Okay.
Perfect. Thank you so much for taking my questions.
Sure.
Thank you we'll take our next question from Charles <unk> with TD Cowen Your line is open.
Yes, Thank you for taking the question.
Question sort of on the fourth quarter guide and just generally how to think of cadence.
Overall, I think pre COVID-19, but fourth quarter was typically our strongest quarter in terms of earnings.
That wasn't the case during the Covid period, and certainly not the case this year.
From tough comps as well as some of the trends you're discussing.
If we think about the range here for the fourth quarter is this a good jumping off point, though is we're kind of going to the ex COVID-19 period. It seems like backlog is kind of normalizing.
Insulation rates are slowing and where maybe get into a more normal period.
And so would we expect the jump off point for the fourth quarter to think of first quarter next year at least sequentially down and getting back to a more normal cadence of earnings.
It depends on what what you mean by jump off point from a growth rate right. Our first our fourth quarter as I indicated in my remarks from an organic revenue.
It's mid single digit decline, which is not.
Think how you should be thinking about the outlook.
For 2024 without putting without <unk>.
Giving any guidance into 2024.
Yes.
I think the fourth quarter is being impacted by comps because we had extraordinarily high performance in the fourth quarter of 2022 with close to 19% growth.
So if youre talking about growth rates have to be careful.
Alright.
I think that our standpoint.
Standpoint.
Yes, so I think from a dollar standpoint, I think I commented earlier, it sort of flattish I think two.
<unk> slightly down versus the third quarter.
Normally our fourth quarter tends to be our largest quarter from a dollar perspective.
But we do as you pointed out I've seen some impacts from the demand environment.
And that plays a little bit into the fourth quarter. We really encourage you guys to look at us on an annualized basis, we have fluctuations quarter to quarter, there's comps when we compare.
Two last year first half second half as we pointed out first heartless.
Relatively lower second half was very strong from a growth rate.
And then there's other things like the timing of the NSP shipments in China as I pointed out.
Great and if I could just quickly.
As you say.
We use the entire year.
And as the jumping off point.
It's what we are saying so we had we've had.
So complicated comps this year and last year first half versus second and vice versa.
The sort of assumption that quarters will be a certain growth rate is almost impossible for us to discern and I think we do a very good job of giving you annual guidance so try to embrace.
What the full year is growth rate and margin is.
As some sort of reasonable jumping off point subject to whatever we do with pricing at whatever volume we can garner.
For the next year, but.
But if you if you just assume that whatever the fourth quarter is just going to continue I think thats going to give you an erroneous result.
Yeah understood.
If I could follow up on that HP.
What is the sort of root cause on the on the <unk>.
The kind of the.
The difference in timing of shipments is that always just been a constant in this business just not very noticeable.
Or just not having needed to be called out until more recently or is there something more specific happening over the last year or so.
Yes.
It's always been there.
We had to call it out because it was sort of unpredictable and the numbers are pretty big impact when we get it is quite positive.
We don't have a lot of control and we have X number of Nhk's available, we have a handful of local client Chinese clients, who want some.
And sometimes that slides they said they want them in a certain quarter.
I'll take some of that I would take all of them.
So it's.
Get a little bit little bit unpredictable, but.
We should add up.
Selling all that we had anticipated.
During this fiscal year.
So we have said earlier numbers of animals available is slightly less than they were a couple.
As ago.
And so that has that practice as well.
Great. Thank you so much.
Sure.
Thank you we'll take our next question from Jack Wallace with Guggenheim Securities. Your line is open.
Hey, Thanks for taking my questions.
Just a quick one on <unk> and again I appreciate all the disclosure.
You recall that there was expected to be about half or certainly less than the.
$190 million or $160 million impact in the back half of the year due to supply constraints.
It looks like there is a solid beat in DSA in the quarter, possibly related to that was there any and HP.
Is that revenue drop their impact you previously called out.
Experienced in the third quarter.
Yeah. So.
I think we've been the team has done an incredible job throughout the year of ensuring we could.
Support the needs of our clients.
And mitigate.
Almost all the impact of the.
Supply disruptions that we were expecting at the beginning of the year and so as a result of that as you saw we actually updated our full year guidance for the DSA segment out of high single digit and so I think the impact of NH be supply disruption.
It really has really been de minimus.
And has allowed us to actually increase the DSA guidance.
Yes, that's fantastic and then quickly over to manufacturing thinking about the.
Testing business.
Just to put the <unk>.
Demand for testing and context for vaccines, roughly where are we today.
And in terms of demand mix versus say pre COVID-19, just trying to get an idea. If there is yes inventories have been.
Diminishing whether theres a snapback here, we're still above.
Elevated level compared to historical norms. Thank you.
I think the historical levels of testing are higher.
The work got sort of high check to Covid.
That should be coming back.
Sure.
Okay.
Now just to pull back the numbers of drugs to be tested just generally that huge emphasis in getting stuff.
Through the clinic again, our biologics business not unlike.
Discovery snaps back quickly catch that back quickly.
Very short term valuable studies with they've just come in with very little notice.
Historically, that's been more of it more of a predictable.
Our experience from next year, but.
We do think that going forward.
We're having back to sort of historical norms.
Discovery.
Biologics business at very good growth rates and margin accretion over the last few years microbial spin are steady.
ROA for 25 years literally.
With exceptional biotech so we do think our CMO business, which nobody's asked about but.
Repaired remarks.
It is performing well growing nicely.
Bunch of regulatory audits several clients.
We move at trough.
Okay clinical case, so the commercial phase.
That will that obviously, it will be accretive to the manufacturing segment's top and bottom lines.
Perfect.
I appreciate it thank you.
Sure. Thank you we'll take our next question from Josh Waldman with Cleveland Research. Your line is open.
Hey, good morning, guys. Thanks for squeezing me in just one here on on DSA Jim.
I guess I wondered if you could comment on any changes youre seeing in the competitive landscape in safety assessment, I'm curious whether demand fluctuations cancellations or maybe capacity availability have resulted in any changes in their recent discounting levels or the broader competitive landscape.
Okay.
We're not.
We are significantly significantly larger deeper science in a much broader footprint.
Our competitiveness and we also have the connectivity of the other parts of our business, particularly.
Discovery.
Aspects of manufacturing.
<unk>.
The manufacturing business so.
Sure.
Why not.
Seeing any fundamental changes that we have smaller competitors I would say that without exception that compete with us primarily in essentially on price.
I think they can do and okay sure.
<unk> toxicology studies for you, but definitely not an okay complex study for you on some of them have a very small footprints.
Very limited.
Capacity so.
I think we're holding taking share I think we're getting price when appropriate.
I won't tell you that we never have aggressive pricing.
We will get aggressive if somebody's attacking our big clients that we have or we are bidding on new de novo business, but.
But generally we feel that over the last few years, we've gotten much better paid for the complexity of our.
Work so.
I don't see the competitive dynamic is going to change it.
Complex expensive business, where you have to have a long history for your clients I. Appreciate you. So I think.
Folks that know better.
Tend to come to us.
Working hard to have sufficient capacity. So we don't turn them away and when I say capacity I'm talking about staffing and facilities and not just facilities in one place but facilities all over the world. So.
We feel particularly good about our competitive posture bolster our businesses, but I would say, particularly in safety.
Got it appreciate the detail.
Thank you we'll take our next question from Tim Daly with Wells Fargo. Your line is open.
Great. Thanks.
For fitting me in here so first just.
Noticed that there wasn't really mentioned this quarter on the call of the recent re org.
Large models safety talks infrastructure.
Kind of a quasi offshoring. So just curious does that mean, we've kind of stabilized all of that set in place.
No more disruptions topline our profits.
And then.
What was the year to date margin headwind from this undertaking the fair to think about that on the.
CSA margins specifically.
So I assume the first part of your question is about.
And HP disruption that we.
And currency that at the beginning of the year at stock might people our profile.
So all that we can tell you is that we have a large international infrastructure.
Multiple sources of supply.
Of which we have an ownership position suddenly a JV and all of that we have long term contracts. So we have sufficient Bruce a and hps.
I can't guarantee anything about future except to tell you that.
We are operating in very good harmony with local regulatory authorities.
We have we have sufficient numbers of very high quality healthy external sources.
We've had no disruption to and with our clients.
I'm really pleased with the way we are handling it.
We will have the same assumption in terms of stability of NHS supply.
As we move into next year for sure.
Alright.
In the next couple of months, which we which we don't anticipate so.
Your question was a little.
But we're looking for some guarantees.
We don't anticipate any disruption.
We're doing everything we can to ensure that we don't have disruption.
And we had disruption at the beginning of the year as we think through no fault of our own.
Our set of circumstances, but right now thanks.
Very stable.
Our client support point of view.
I'll take the second part of that question.
Yes.
The second part in terms of impact to margin I think the DSA margin, both on the quarter and on a year to date basis.
That's been strong and so as Jim said I think we've done that our teams have done a tremendous job on making sure that we navigated.
This situation and.
There was practically no impact into the margin of any supply.
Movement that we made to accommodate the demand.
Alright got it.
That's really helpful and Jim just a follow.
A follow up here on the supply side of things in the <unk>.
<unk> 10-Q filing there was a mention of a post quarter end the acquisition of the majority stake of a prior JV.
Large animal model supplier in the DSA business.
I think kind of grossing it up gets to almost a half a billion dollar valuation for that.
So could you just please provide us some detail on that.
Location.
Plan.
Strategy.
Some help there would be great.
Thank you sure sure so I can't be too specific since it hasn't closed yet but.
The first tranche.
We bought so we aren't a big piece of this business.
So very high quality source of supply that we've worked with for years.
Hi.
Quite confident that the restaurant will close we will essentially on that site.
And obviously, we will participate in brining our site hopefully expanding it over time and that just that's another way to ensure the.
The availability of high quality monkeys or.
Okay.
It's a particularly good location will be able to give you clarity on that.
Hopefully not too distant future, who it is where it is and what the.
Positive ramifications are.
Alright look forward to it.
Thanks.
I think that was probably the last question we had before we wrap up I do want to go back to Derek's question on math on the $3 per share of <unk> pricing as you suggested.
Because that would mean that almost all of the $235 million of cumulative benefit of any speed pricing that we share with all of you over the past three years, we have Jonathan down to Oi and EPS.
It's just not true because all costs from an HP supply is also have gone up meaningfully over the last three years.
And so we're not going to provide details on how much they increase for competitive reasons as you might imagine.
But I can assure you that the costs have come up meaningfully so the math on the $3 per share.
I think overstate that significantly.
Thank you we have no further questions in queue I will turn the conference back to Todd Spencer for closing remarks.
Great. Thank you for joining us on the conference call. This morning, we look forward to seeing you at upcoming Investor conferences and have a great day. Thank you. This concludes the call.
Thank you that does conclude today's Charles River Laboratories third quarter 2023 earnings call. Thank you for your participation you may now disconnect.
[music].
Mhm.
Hmm.
Hum.
[music].
Hello.
Oh.
[music].
Hum.
Hum.
Hum.
Yeah.
Okay.
[music].
Yeah.
[music].
Yes.
Okay.
[music].
Yes.
[music].
Okay.
Yes.
[music].
Yes.
[music].
Yes.
[music].
Yes.
[music].
Okay.
[music].
Yes.
[music].
Yes.
[music].
Yes.
Yes.
[music].
Okay.
[music].
Okay.
[music].
Yes.
Okay.
Okay.
[music].
Alright.
Yes.
Okay.
[music].
Yes.
[music].
Yes.
Yes.
[music].
Yeah.
Okay.
[music].
Yeah.
Okay.
Sure.
[music].
Okay.
Yes.
[music].
Okay.
[music].
Okay.
Yes.
Yes.
[music].
Okay.
[music].
Yes.
[music].
Okay.
Yes.
Sure.
Sure.
[music].
Okay.
Yes.
Okay.
Yes.
[music].
Okay.
Yes.
Yes.
Okay.
Okay.
Sure.
Yes.
Okay.
Yes.
Yes.
Yes.
Yes.
Okay.
Yes.
Yes.
[music].
Thanks.
Okay.
Okay.
Okay.
Thank you.
Thank you.
Yes.
[music].
Okay.
[music].
Yes.
Sure.
[music].
Yes.
Yes.
Sure.
Okay.
Okay.
Yes.
Yes.
Okay.
Yes.
Okay.
Okay.
[music].
Yes.
Sure.
Yes.
Yes.
Yes.
Okay.
Yes.
Thanks.
Yes.
Yes.
Yes.
Okay.
[music].
Yes.
[music].
Okay.
Yes.
Yes.
Great.
[music].
Okay.
Sure.
Okay.
Okay.
Okay.
Okay.
Okay.
Sure.
Yes.
Okay.
[music].
Okay.
[music].
Thanks.
Yes.
Okay.
[music].
Yes.
Yes.
Okay.
Okay.
[music].
Yeah.
Okay.
Okay.
Yes.
[music].
Okay.
Sure.
Okay.
Yes.
Please.
Yes.
Yes.
[music].
Okay.
Yes.
Okay.
Yes.
Sure.
Okay.
Yes.
Okay.
Okay.
Thank you.
Yes.
Sure.
[music].
Okay.
Yes.
Yes.
Okay.
Yes.
[music].
Yes.
Okay.
[music].
Yes.
Yes.
Okay.
Yes.
Okay.
Yes.
[music].